Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | TTBK1 | Q5TCY1 | 4/20 | 0.45 |
| ▸ | TTBK2 | Q6IQ55 | 4/20 | 0.45 |
| ▸ | JAK2 | O60674 | 4/20 | 0.42 |
| ▸ | JAK1 | P23458 | 4/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 4/20 | 0.40 |
| ▸ | TYK2 | P29597 | 3/20 | 0.40 |
| ▸ | BTK | Q06187 | 2/20 | 0.40 |
| ▸ | BMX | P51813 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7848307 | 0.92 | PDPK1 (0.48) | HPGDSTTBK1TTBK2JAK2JAK1 | |
| SCHEMBL3535943 | 0.84 | TTBK1 (0.49) | HPGDSTTBK1TTBK2JAK2JAK1 | |
| SCHEMBL193515 | 0.79 | AURKA (0.57) | HPGDSTTBK1TTBK2JAK2JAK1 | |
| SCHEMBL6746641 | 0.79 | AURKA (0.57) | HPGDSTTBK1TTBK2JAK2JAK1 | |
| SCHEMBL12561873 | 0.76 | JAK2 (0.61) | HPGDSTTBK1TTBK2JAK2JAK1 | |
| SCHEMBL8930214 | 0.75 | AURKA (0.59) | HPGDSTTBK1TTBK2IRAK4BTK | |
| SCHEMBL3534101 | 0.74 | JAK1 (0.66) | HPGDSTTBK1TTBK2JAK2JAK1 | |
| SCHEMBL3534327 | 0.74 | JAK2 (0.70) | HPGDSTTBK1TTBK2JAK2JAK1 | |
| Hydrochloric Acid SCHEMBL8929656 | 0.74 | AURKA (0.58) | HPGDSTTBK1TTBK2IRAK4BTK | |
| SCHEMBL3535218 | 0.73 | JAK1 (0.68) | HPGDSTTBK1TTBK2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687507-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| US-6890929-B2 | Immunosuppressants; lupus, multiple sclerosis, skin disorders, antiarthritic agents, antihistamines, antiulcer agents, Crohn's disease | PFIZER, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1087970-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-6610847-B2 | Tyrosine kinase inhibitors; immunosuppressants | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | HPGDS 785/4885TTBK1 126/4885TTBK2 242/4885 |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK3, JAK1, JAK2 | HPGDS 649/4885TTBK1 114/4885TTBK2 184/4885 |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | JAK1, JAK3, JAK2 | HPGDS 785/4885TTBK1 126/4885TTBK2 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.